Merck's current discounted valuation, and robust pipeline advancements, which tripled over the past 3+ years, present a compelling long-term investment opportunity. Its strong business performance ...

Q4 2024 Management View Co-CEO Jim Teague highlighted that in 2024, the company achieved $9.9 billion in EBITDA and $7.8 billion in distributable cash flow (DCF) with a coverage ratio of 1.7 times. He ...